Race, gender, drug use, and participation in AIDS clinical trials: Lessons from a municipal hospital cohort

Journal of General Internal Medicine

Volumn 12, Issue 3, 1997, Pages 150-157

  Stone, Valerie E ^a,d,e,g   Mauch, Maya Y ^d   Steger, Kathleen ^c,d,e   Janas, Stephen F ^c   Craven, Donald E ^b,d,f  

^a Section of General Internal Medicine   (United States)

^b Section of Infectious Diseases   (United States)

^c Boston University Medical Campus   (United States)

^d City Hospital   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^f University School of Public Health   (United States)

^g MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

AIDS; clinical trials; injection drug use; race; women

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH BEHAVIOR; HEALTH CARE UTILIZATION; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; SEX DIFFERENCE;

EID: 0030887627     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.1997.012003150.x     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR. 1992;41(RR-17):1-11.
2. Centers for Disease Control and Prevention. Update: AIDS among women - United States. 1994. MMWR. 1995;44(5):81-4.
3. Centers for Disease Control and Prevention. Update: AIDS - United States. 1994. MMWR. 1995;44(5):64-7.
4. Centers for Disease Control and Prevention. HIV/AIDS Surveill Rep (Year-End-Ed). 1995;7(2):5,10-2.
5. Centers for Disease Control and Prevention. Update: Mortality attributable to HIV Infection among persons aged 25-44 years - United States 1991 and 1992. MMWR. 1993:42(45):869-72.
6. Despite gains. NIAID AIDS clinical trials need to increase minority representation. Nat Med Assoc News. Winter 1994:3.
7. Cotton DJ, Finkelstein DM, He W, Feinberg J. Determinants of accrual of women to a large, multicenter clinical trials program of human immunodeficiency virus infection. J Acquir Immune Defic Syndr. 1993;6:1322-8.
8. El-Sadr W, Capps L. The challenge of minority recruitment in clinical trials for AIDS. JAMA. 1992;267:954-8.
9. Craven DE, Liebman HA, Fuller J, et al. AIDS in intravenous drug users: Issues related to enrollment in clinical trials. J Acquir Immune Defic Syndr. 1990:S45-50.
10. Smith MD. Zidovudine: does it work for everyone? JAMA. 1991; 266:2750-1.
11. Murphy TF. Women and drug users: the changing faces of HIV clinical trials. Qual Rev Bull. 1991:26-32.
12. Jacobson M, Maier C. Issues for women participating in clinical trials. AIDSFILE. 1991;5(3):6-8.
13. Bennett JC. Inclusion of women in clinical trials-policies for population subgroups. N Engl J Med. 1993;329:288-91.
14. Bylar DP, Schoenfeld DA, Green SB, et al. Design considerations for AIDS trials. N Engl J Med. 1990;323:1343-8.
15. Merkatz RB, Temple R, Sobel S, et al. Women in clinical trials of new drugs - a change in food and drug administration policy. N Engl J Med. 1993;329:292-6.
16. Ness RB, Grisson JA. Clinical research and minorities: how difficult is it? SGIM Forum. 1994;17:1,6.
17. Gamble VN. A legacy of distrust: African Americans and medical research. Am J Prev Med. 1993;9(suppl):35-8.
18. Centers for Disease Control and Prevention. HIV/AIDS Surveill Rep. 1993;5:18-9.
19. Huth EJ. Identifying ethnicity in medical papers. Ann Intern Med. 1995;22:619-21.
20. Medrano L, Klopner MC. AIDS and persons of color. In: Land HM, ed. AIDS: A Complete Guide to Psychosocial Intervention. Milwaukee, Wis: Family Service America: 1992:117-39.
21. Rich JA. HIV infection in communities of color. In: Libman H, Witburg RA, eds. HIV Infection: A Clinical Manual. Boston. Mass: Little. Brown and Co; 1996:651-62.
22. Stone VE, Weissman JS, Cleary PD. Satisfaction with ambulatory care of persons with AIDS: predictors of patient ratings of quality. J Gen Intern Med. 1995;10:239-45.
23. Jones J. Bad Blood: The Tuskegee Syphilis Experiment. New York. NY: Free Press; 1981.
24. McCabe MS, Varricchio CG, Padberg RM. Efforts to recruit the economically disadvantaged to national clinical trials. Semin Oncol Nurs. 1994;10:123-9.
25. Swanson GM, Ward AJ. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst. 1995;87: 1747-59.
26. Minority enrollment below target levels for NCI's chemopreventive prostate cancer prevention trial. Natl Med Assoc News. Spring 1995:5-6.
27. Thomas CR, Pinto HA, Roach M, Vaughn CB. Participation in clinical trials: is it state of the art treatment for African Americans and other people of color? J Natl Med Assoc. 1994;86:177-82.
28. Allen M. The dilemma for women of color in clinical trials. J Am Med Wom Assoc. 1994;49(4):105-9.
29. Woloshin S, Bickell NA, Schwartz LM, Gany F, Welch G. Language barriers in medicine in the United States. JAMA. 1995;273:724-8.
30. Diaz T, Buehler JW, Castro KG, Ward JW. AIDS trends among Hispanics in the United States. Am J Public Health. 1993;83:504-9.
31. Report says research must enroll more women. Physician's News Digest. April 1994:13.
32. Pinn VW. Women's health research: prescribing change and addressing the issues. JAMA. 1992;268:1921-2.
33. Tschida M. Beyond the seventy kilogram man. New Physician. March 1995:12-22.
34. Angell M. Caring for women's health - what is the problem? N Engl J Med. 1993;329:271-2.
35. Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford C, McGowan JA. The evolution of the women's health initiative: perspectives from the NIH. J Am Med Wom Assoc. 1995;50:50-5.
36. Samet JH, Libman HA, Dhawan RK, et al. Compliance with zidovudine in patients infected with HIV-1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495-502.
37. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection drug users with HIV infection. N Engl J Med. 1994;331:450-9.
38. Solomon L, Frank FR, Vlahov D, Astemborski J. Utilization of health services in a cohort of intravenous drug use with known HIV-1 serostatus. Am J Public Health. 1991;81:1285-90.
39. Selwyn PA, Ferngold AR, Iezza A, et al. Primary care for patients with HIV in a methadone maintenance treatment program. Ann Intern Med. 1989;11:761-3.
40. Kissinger P, Cohen D, Brandon W, et al. Compliance with public sector HIV medical care. J Natl Med Assoc. 1995;87:19-24.
41. Morse EV, Simon PM, Coburn M, et al. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med. 1991;32:1161-7.